Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6.8% – Here’s Why

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s share price rose 6.8% during trading on Tuesday . The company traded as high as $1.64 and last traded at $1.57. Approximately 504,142 shares traded hands during trading, an increase of 55% from the average daily volume of 325,877 shares. The stock had previously closed at $1.47.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $13.00 target price on shares of Enlivex Therapeutics in a report on Tuesday, July 29th.

Enlivex Therapeutics Price Performance

The stock has a market cap of $37.13 million, a price-to-earnings ratio of -2.38 and a beta of 0.80. The stock has a fifty day moving average of $1.20 and a 200 day moving average of $1.08.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Friday, May 30th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. As a group, equities analysts expect that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Two Sigma Securities LLC acquired a new position in Enlivex Therapeutics in the fourth quarter valued at approximately $26,000. Jane Street Group LLC lifted its holdings in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares during the period. Renaissance Technologies LLC lifted its holdings in Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after acquiring an additional 84,203 shares during the period. Finally, Millennium Management LLC acquired a new position in Enlivex Therapeutics in the fourth quarter valued at approximately $742,000. 1.02% of the stock is owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.